Mitarbeiter: 21 (2023.0)Rechtsform: SCA (commandite par actions)Größe: ETIGründungsdatum: 2004-05-25 (21 Jahre)Status: AktivBranche: Commerce de gros (commerce interentreprises) de produits pharmaceutiquesStandort: RUEIL-MALMAISON (92500), Hauts-de-Seine
OTSUKA PHARMACEUTICAL FRANCE SAS : revenue, balance sheet and financial ratios
OTSUKA PHARMACEUTICAL FRANCE SAS is a French company
founded 21 years ago,
specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques.
Based in RUEIL-MALMAISON (92500),
this company of category ETI
shows in 2024 a revenue of 66.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Historique financier - OTSUKA PHARMACEUTICAL FRANCE SAS (SIREN 453720336)
Kennzahl
2024
2023
2022
2021
2020
2019
2018
2017
2016
Umsatz
66 356 108 €
69 870 406 €
67 433 947 €
68 606 292 €
71 953 958 €
64 923 929 €
54 978 534 €
57 645 280 €
66 934 898 €
Nettoergebnis
943 677 €
691 091 €
919 713 €
1 088 764 €
616 356 €
753 198 €
207 779 €
-870 228 €
442 663 €
EBITDA
2 377 998 €
2 800 569 €
908 995 €
359 464 €
7 381 739 €
2 909 960 €
2 261 526 €
3 409 565 €
2 819 784 €
Nettomarge
1.4%
1.0%
1.4%
1.6%
0.9%
1.2%
0.4%
-1.5%
0.7%
Umsatz und Gewinn- und Verlustrechnung
In 2024, OTSUKA PHARMACEUTICAL FRANCE SAS achieves revenue of 66.4 M€. Activity remains stable over the period (CAGR: -0.1%). Slight decline of -5% vs 2023. After deducting consumption (47.2 M€), gross margin stands at 19.1 M€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.4 M€, representing 3.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 944 k€, i.e. 1.4% of revenue. This profit can be retained or distributed to shareholders.
Umsatz (2024)
?
Umsatz
Definition
Gesamtbetrag der Verkäufe von Waren und Dienstleistungen des Unternehmens.
Formel
Warenverkäufe + Verkaufte Produktion
66 356 108 €
Bruttomarge (2024)
?
Bruttomarge
Definition
Differenz zwischen Umsatz und Wareneinsatz.
Formel
Umsatz - Wareneinsatz
19 146 085 €
EBITDA (2024)
?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit
2 377 998 €
EBIT (2024)
?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen
1 833 342 €
Nettoergebnis (2024)
?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Le compte de résultat détaillé n'est pas disponible pour cette entreprise (liasse simplifiée ou données confidentielles).
Évolution graphique
Anzeigen :
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Aktiva
Chargement des données...
Poste
Brutto
Abschr.
Netto
%
Entwicklung
Données de bilan actif non disponibles pour cette entreprise
Passiva
Chargement des données...
Poste
Jahr
%
Entwicklung
Données de bilan passif non disponibles pour cette entreprise
Solvenz- und Verschuldungskennzahlen
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 13%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 1.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Verschuldungsgrad (2024)
?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible 50-100% : Moderat > 100% : Hoch
0.0%
Finanzielle Autonomie (2024)
?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Entwicklung der Solvenzkennzahlen OTSUKA PHARMACEUTICAL FRANCE SAS
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Verschuldungsgrad
1.441
1.743
0.226
0.0
0.112
0.006
0.0
0.0
0.0
Finanzielle Autonomie
35.193
23.769
23.655
24.892
25.468
25.902
8.73
8.377
12.84
Rückzahlungsfähigkeit
0.051
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Cashflow / Umsatz
1.363%
-0.275%
0.841%
1.794%
7.383%
-1.715%
-0.778%
1.111%
1.275%
Positionnement sectoriel
Debt ratio
0.02024
2022
2023
2024
Q1: 0.0
Méd: 4.27
Q3: 43.96
Excellent
In 2024, the debt ratio of OTSUKA PHARMACEUTICAL FRA... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
12.84%2024
2022
2023
2024
Q1: 14.64%
Méd: 38.36%
Q3: 60.56%
Average
In 2024, the financial autonomy of OTSUKA PHARMACEUTICAL FRA... (12.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
0.0 years2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.0 years
Q3: 1.09 years
Excellent
In 2024, the repayment capacity of OTSUKA PHARMACEUTICAL FRA... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquiditätskennzahlen
The liquidity ratio (= Current assets / Current liabilities) stands at 129.01. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquiditätsquote (2024)
?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut 1-1.5 : Angemessen < 1 : Risque de liquidité
129.01
Zinsdeckung (2024)
?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Entwicklung der Liquiditätskennzahlen OTSUKA PHARMACEUTICAL FRANCE SAS
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquiditätsquote
159.818
138.331
138.638
142.471
179.201
160.279
118.964
118.71
129.01
Zinsdeckung
12.28
3.345
0.0
0.385
0.0
0.0
0.0
0.0
0.0
Positionnement sectoriel
Liquidity ratio
129.012024
2022
2023
2024
Q1: 132.74
Méd: 202.27
Q3: 325.9
Watch
In 2024, the liquidity ratio of OTSUKA PHARMACEUTICAL FRA... (129.01) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
0.0x2024
2022
2023
2024
Q1: 0.0x
Méd: 0.41x
Q3: 6.25x
Average
In 2024, the interest coverage of OTSUKA PHARMACEUTICAL FRA... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Umlaufvermögensbedarf und Zahlungsfristen
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 50 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 30 days. The company must finance 20 days of gap between collections and payments. Overall, WCR represents 44 days of revenue, i.e. 8.0 M€ to permanently finance. Notable WCR improvement over the period (-40%), freeing up cash.
Operatives Working Capital (2024)
?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität
30 j
Lagerumschlag (2024)
?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag
0 j
Working Capital in Umsatztagen (2024)
?
Working Capital in Umsatztagen
Definition
Drückt den Betriebskapitalbedarf in Umsatztagen aus.
Formel
(BFR exploitation / CA) x 360
Interpretation
Je weniger Tage, desto besser das Working Capital Management
44 j
Entwicklung des Working Capital und der Zahlungsfristen OTSUKA PHARMACEUTICAL FRANCE SAS
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
BFR d'exploitation
13 316 698 €
8 663 509 €
10 873 654 €
13 061 396 €
14 847 699 €
16 263 122 €
9 001 083 €
8 754 063 €
8 028 426 €
Lagerumschlag (Tage)
0
0
0
0
0
0
0
0
0
Crédit clients (jours)
30
64
58
60
62
58
60
55
50
Crédit fournisseurs (jours)
36
23
40
38
14
37
35
35
30
Positionnement de OTSUKA PHARMACEUTICAL FRANCE SAS dans son secteur
Vergleich mit der Branche Commerce de gros (commerce interentreprises) de produits pharmaceutiques
Bewertungsschätzung
Based on 124 transactions of similar company sales
(all years),
the value of OTSUKA PHARMACEUTICAL FRANCE SAS is estimated at
5 231 613 €
(range 2 753 713€ - 16 454 254€).
With an EBITDA of 2 377 998€, the sector multiple of 0.7x is applied.
The price/revenue ratio is 0.21x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
124 transactions
2753k€5231k€16454k€
5 231 613 €Range: 2 753 713€ - 16 454 254€
NAF 5 all-time
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
2 377 998 €×0.7x
Estimation1 673 837 €
791 283€ - 6 092 158€
Revenue Multiple30%
66 356 108 €×0.21x
Estimation14 132 152 €
7 663 531€ - 42 806 522€
Net Income Multiple20%
943 677 €×0.8x
Estimation775 245 €
295 064€ - 2 831 098€
Bewertungsentwicklung
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)
Compare OTSUKA PHARMACEUTICAL FRANCE SAS with other companies in the same sector:
Frequently asked questions about OTSUKA PHARMACEUTICAL FRANCE SAS
What is the revenue of OTSUKA PHARMACEUTICAL FRANCE SAS ?
The revenue of OTSUKA PHARMACEUTICAL FRANCE SAS in 2024 is 66.4 M€.
Is OTSUKA PHARMACEUTICAL FRANCE SAS profitable?
Yes, OTSUKA PHARMACEUTICAL FRANCE SAS generated a net profit of 944 k€ in 2024.
Where is the headquarters of OTSUKA PHARMACEUTICAL FRANCE SAS ?
The headquarters of OTSUKA PHARMACEUTICAL FRANCE SAS is located in RUEIL-MALMAISON (92500), in the department Hauts-de-Seine.
Where to find the tax return of OTSUKA PHARMACEUTICAL FRANCE SAS ?
The tax return of OTSUKA PHARMACEUTICAL FRANCE SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does OTSUKA PHARMACEUTICAL FRANCE SAS operate?
OTSUKA PHARMACEUTICAL FRANCE SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Drehen Sie Ihr Telefon ins Querformat, um das Diagramm anzuzeigen